Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

Moderna has struggled since COVID-19 vaccine demand has shrunk. The stock has correspondingly declined, as revenue has nosedived over the last few years. The long game is clinical trials in oncology ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Versant Capital Management Inc grew its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 408.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The ...

In the short term, Moderna (NASDAQ: MRNA) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I ...